Relacorilant + nab-paclitaxel for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Feb 2022: Trial registered, NCT05257408
  2. 29 Jun 2022: Trial started, NCT05257408

The trials

NCT05257408: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

State
Under way
Phase
Phase 3
People
381 taking part
Started
29 Jun 2022
Primary completion
31 Mar 2025
Arms
Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2
Results
Posted on the registry
  1. 25 Feb 2022: Trial registered
  2. 29 Jun 2022: Trial started
  3. 25 Sep 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.